Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease.

Strange JE, Sindet-Pedersen C, Staerk L, Grove EL, Gerds TA, Torp-Pedersen C, Gislason GH, Olesen JB.

Eur Heart J Cardiovasc Pharmacother. 2020 Feb 17. pii: pvaa011. doi: 10.1093/ehjcvp/pvaa011. [Epub ahead of print]

PMID:
32065652
2.

Real-world effectiveness and safety of pharmacological thromboprophylaxis in patients undergoing primary total hip and knee arthroplasty: A narrative review.

Schelde AB, Eliasen A, Olesen JB, Jensen TB, Jimenez-Solem E.

J Orthop. 2019 Nov 12;19:166-173. doi: 10.1016/j.jor.2019.11.012. eCollection 2020 May-Jun. Review.

PMID:
32025127
3.

Secondary stroke prophylaxis in atrial fibrillation patients with chronic kidney disease: a nationwide cohort study.

Christensen MA, Fosbøl EL, Bonde AN, Olesen JB, Gislason GH, Torp-Pedersen C, Gundlund A.

Europace. 2019 Dec 23. pii: euz340. doi: 10.1093/europace/euz340. [Epub ahead of print]

PMID:
31872246
4.

One-year outcomes in atrial fibrillation presenting during infections: a nationwide registry-based study.

Gundlund A, Olesen JB, Butt JH, Christensen MA, Gislason GH, Torp-Pedersen C, Køber L, Kümler T, Fosbøl EL.

Eur Heart J. 2019 Dec 17. pii: ehz873. doi: 10.1093/eurheartj/ehz873. [Epub ahead of print]

PMID:
31848584
5.

Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study.

Schjerning Olsen AM, McGettigan P, Gerds TA, Fosbøl EL, Olesen JB, Sindet-Pedersen C, Staerk L, Hansen ML, Pallisgaard JL, Køber L, Torp-Pedersen C, Gislason GH, Lamberts M.

Eur Heart J Cardiovasc Pharmacother. 2019 Nov 19. pii: pvz069. doi: 10.1093/ehjcvp/pvz069. [Epub ahead of print]

PMID:
31742339
6.

Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study.

Laugesen EK, Staerk L, Carlson N, Kamper AL, Olesen JB, Torp-Pedersen C, Gislason G, Bonde AN.

Thromb J. 2019 Nov 12;17:21. doi: 10.1186/s12959-019-0211-y. eCollection 2019.

7.

Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose.

Vinding NE, Staerk L, Gislason GH, Torp-Pedersen C, Bonde AN, Rørth R, Lee CJ, Olesen JB, Køber L, Fosbøl EL.

Eur Heart J Cardiovasc Pharmacother. 2019 Nov 15. pii: pvz066. doi: 10.1093/ehjcvp/pvz066. [Epub ahead of print]

PMID:
31730151
8.

Vitamin K Antagonists versus Direct Oral Anticoagulants After Transcatheter Aortic Valve Implantation in Atrial Fibrillation.

Butt JH, De Backer O, Olesen JB, Gerds TA, Havers-Borgersen E, Gislason GH, Torp-Pedersen C, Søndergaard L, Køber L, Fosbøl EL.

Eur Heart J Cardiovasc Pharmacother. 2019 Oct 26. pii: pvz064. doi: 10.1093/ehjcvp/pvz064. [Epub ahead of print]

PMID:
31665260
9.

Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Left-Sided Heart Valve Surgery.

Butt JH, Olesen JB, Gundlund A, Kümler T, Olsen PS, Havers-Borgersen E, Aagaard DT, Gislason GH, Torp-Pedersen C, Køber L, Fosbøl EL.

JAMA Cardiol. 2019 Oct 9. doi: 10.1001/jamacardio.2019.3649. [Epub ahead of print]

PMID:
31596426
10.

Comparative thromboembolic risk in atrial fibrillation with and without a secondary precipitant-Danish nationwide cohort study.

Gundlund A, Kümler T, Bonde AN, Butt JH, Gislason GH, Torp-Pedersen C, Køber L, Olesen JB, Fosbøl EL.

BMJ Open. 2019 Sep 20;9(9):e028468. doi: 10.1136/bmjopen-2018-028468.

11.

Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study.

Xing LY, Barcella CA, Sindet-Pedersen C, Bonde AN, Gislason GH, Olesen JB.

Thromb Res. 2019 Jun;178:101-109. doi: 10.1016/j.thromres.2019.04.007. Epub 2019 Apr 9.

PMID:
31004965
12.

Catabolic activity of osteoblast lineage cells contributes to osteoclastic bone resorption in vitro.

Pirapaharan DC, Olesen JB, Andersen TL, Christensen SB, Kjærsgaard-Andersen P, Delaisse JM, Søe K.

J Cell Sci. 2019 May 15;132(10). pii: jcs229351. doi: 10.1242/jcs.229351.

13.

Oral anticoagulation among atrial fibrillation patients with anaemia: an observational cohort study.

Bonde AN, Blanche P, Staerk L, Gerds TA, Gundlund A, Gislason G, Torp-Pedersen C, Lip GYH, Hlatky MA, Olesen JB.

Eur Heart J. 2019 Dec 7;40(46):3782-3790. doi: 10.1093/eurheartj/ehz155.

PMID:
30932145
14.

The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.

Vinding NE, Bonde AN, Rørth R, Lamberts M, Olesen JB, Gislason GH, Torp-Pedersen C, Køber L, Fosbøl EL.

Europace. 2019 Apr 1;21(4):572-580. doi: 10.1093/europace/euy262.

PMID:
30508073
15.

Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery.

Butt JH, Olesen JB, Havers-Borgersen E, Gundlund A, Andersson C, Gislason GH, Torp-Pedersen C, Køber L, Fosbøl EL.

J Am Coll Cardiol. 2018 Oct 23;72(17):2027-2036. doi: 10.1016/j.jacc.2018.07.088.

16.

Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.

Sindet-Pedersen C, Lamberts M, Staerk L, Nissen Bonde A, Berger JS, Pallisgaard JL, Lock Hansen M, Torp-Pedersen C, Gislason GH, Olesen JB.

J Am Coll Cardiol. 2018 Oct 9;72(15):1790-1800. doi: 10.1016/j.jacc.2018.07.054.

17.

Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control.

Bonde AN, Staerk L, Lee CJ, Vinding NE, Bang CN, Torp-Pedersen C, Gislason G, Lip GYH, Olesen JB.

J Am Coll Cardiol. 2018 Sep 18;72(12):1357-1365. doi: 10.1016/j.jacc.2018.06.065.

18.

Comparative thromboembolic risk in atrial fibrillation patients with and without a concurrent infection.

Gundlund A, Kümler T, Olesen JB, Bonde AN, Gislason GH, Torp-Pedersen C, Køber L, Fosbøl EL.

Am Heart J. 2018 Oct;204:43-51. doi: 10.1016/j.ahj.2018.07.003. Epub 2018 Jul 10.

PMID:
30075325
19.

Real-Time 2-D Phased Array Vector Flow Imaging.

Holbek S, Hansen KL, Fogh N, Moshavegh R, Olesen JB, Nielsen MB, Jensen JA.

IEEE Trans Ultrason Ferroelectr Freq Control. 2018 Jul;65(7):1205-1213. doi: 10.1109/TUFFC.2018.2838518.

PMID:
29993373
20.

Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation.

Lee CJ, Gerds TA, Carlson N, Bonde AN, Gislason GH, Lamberts M, Olesen JB, Pallisgaard JL, Hansen ML, Torp-Pedersen C.

J Am Coll Cardiol. 2018 Jul 3;72(1):17-26. doi: 10.1016/j.jacc.2018.04.036.

21.

Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study.

Sindet-Pedersen C, Staerk L, Pallisgaard JL, Gerds TA, Berger JS, Torp-Pedersen C, Gislason GH, Olesen JB.

Eur Heart J Cardiovasc Pharmacother. 2018 Oct 1;4(4):220-227. doi: 10.1093/ehjcvp/pvy021.

PMID:
29945162
22.

A Comparison Study of Vector Velocity, Spectral Doppler and Magnetic Resonance of Blood Flow in the Common Carotid Artery.

Brandt AH, Hansen KL, Ewertsen C, Holbek S, Olesen JB, Moshavegh R, Thomsen C, Jensen JA, Nielsen MB.

Ultrasound Med Biol. 2018 Aug;44(8):1751-1761. doi: 10.1016/j.ultrasmedbio.2018.05.002. Epub 2018 May 24.

PMID:
29804906
23.

Reply: Oral anticoagulation and hip fracture risk: a common misconception?

Gundlund A, Fosbøl EL, Gislason GH, Olesen JB.

J Intern Med. 2018 Sep;284(3):323-324. doi: 10.1111/joim.12774. Epub 2018 Jun 10. No abstract available.

PMID:
29797617
24.

Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study.

Christiansen CB, Torp-Pedersen C, Olesen JB, Gislason G, Lamberts M, Carlson N, Buron M, Juul N, Lip GYH.

BMC Cardiovasc Disord. 2018 May 10;18(1):91. doi: 10.1186/s12872-018-0825-1.

25.

Accuracy and Precision of a Plane Wave Vector Flow Imaging Method in the Healthy Carotid Artery.

Jensen J, Hoyos CAV, Traberg MS, Olesen JB, Tomov BG, Moshavegh R, Holbek S, Stuart MB, Ewertsen C, Hansen KL, Thomsen C, Nielsen MB, Jensen JA.

Ultrasound Med Biol. 2018 Aug;44(8):1727-1741. doi: 10.1016/j.ultrasmedbio.2018.03.017. Epub 2018 May 4.

PMID:
29735315
26.

Noninvasive Estimation of Pressure Changes Using 2-D Vector Velocity Ultrasound: An Experimental Study With In Vivo Examples.

Olesen JB, Villagomez-Hoyos CA, Moller ND, Ewertsen C, Hansen KL, Nielsen MB, Bech B, Lonn L, Traberg MS, Jensen JA.

IEEE Trans Ultrason Ferroelectr Freq Control. 2018 May;65(5):709-719. doi: 10.1109/TUFFC.2018.2808328.

PMID:
29733275
27.

Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation.

Butt JH, Xian Y, Peterson ED, Olsen PS, Rørth R, Gundlund A, Olesen JB, Gislason GH, Torp-Pedersen C, Køber L, Fosbøl EL.

JAMA Cardiol. 2018 May 1;3(5):417-424. doi: 10.1001/jamacardio.2018.0405. Erratum in: JAMA Cardiol. 2018 Jun 1;3(6):505.

28.

Renal Function, Time in Therapeutic Range and Outcomes in Warfarin-Treated Atrial Fibrillation Patients: A Retrospective Analysis of Nationwide Registries.

Bonde AN, Lip GYH, Kamper AL, Staerk L, Torp-Pedersen C, Gislason G, Olesen JB.

Thromb Haemost. 2017 Dec;117(12):2291-2299. doi: 10.1160/TH17-03-0198. Epub 2017 Dec 6.

PMID:
29212117
29.

Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study.

Staerk L, Fosbøl EL, Lamberts M, Bonde AN, Gadsbøll K, Sindet-Pedersen C, Holm EA, Gerds TA, Ozenne B, Lip GYH, Torp-Pedersen C, Gislason GH, Olesen JB.

Eur Heart J. 2018 May 14;39(19):1698-1705a. doi: 10.1093/eurheartj/ehx598.

PMID:
29165556
30.

Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011-2016.

Dukanovic A, Staerk L, Fosbøl EL, Gadsbøll K, Gislason GH, Olesen JB.

Thromb Res. 2017 Dec;160:19-26. doi: 10.1016/j.thromres.2017.10.010. Epub 2017 Oct 16.

PMID:
29080549
31.

Reply to 'important factors affecting the choice of an oral anticoagulant may be missed in database studies'.

Gundlund A, Fosbøl EL, Olesen JB.

J Intern Med. 2018 Feb;283(2):216. doi: 10.1111/joim.12693. Epub 2017 Oct 13. No abstract available.

32.

Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.

Staerk L, Gerds TA, Lip GYH, Ozenne B, Bonde AN, Lamberts M, Fosbøl EL, Torp-Pedersen C, Gislason GH, Olesen JB.

J Intern Med. 2018 Jan;283(1):45-55. doi: 10.1111/joim.12683. Epub 2017 Sep 21.

33.

Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation.

Fosbøl EL, Vinding NE, Lamberts M, Staerk L, Gundlund A, Gadsbøll K, Køber L, Gislason GH, Olesen JB.

Europace. 2018 Jun 1;20(6):e78-e86. doi: 10.1093/europace/eux193.

PMID:
28666358
34.

Antithrombotic Therapy and First Myocardial Infarction in Patients With Atrial Fibrillation.

Lee CJ, Pallisgaard JL, Olesen JB, Carlson N, Lamberts M, Gislason GH, Torp-Pedersen C, Brandes A, Husted SE, Johnsen SP, Hansen ML.

J Am Coll Cardiol. 2017 Jun 20;69(24):2901-2909. doi: 10.1016/j.jacc.2017.04.033.

35.

Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism - A Danish nationwide cohort study.

Sindet-Pedersen C, Pallisgaard JL, Staerk L, Berger JS, Lamberts M, Torp-Pedersen C, Gislason GH, Olesen JB.

Sci Rep. 2017 Jun 13;7(1):3347. doi: 10.1038/s41598-017-03596-x.

36.

Familial clustering of atrial fibrillation and comparative longitudinal outcomes of familial and non-familial atrial fibrillation.

Gundlund A, Olesen JB, Peterson ED, Gislason GH, Fosbøl EL.

J Comp Eff Res. 2017 May 9. doi: 10.2217/cer-2016-0088. [Epub ahead of print]

PMID:
28485191
37.

Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?

Gundlund A, Staerk L, Fosbøl EL, Gadsbøll K, Sindet-Pedersen C, Bonde AN, Gislason GH, Olesen JB.

J Intern Med. 2017 Aug;282(2):164-174. doi: 10.1111/joim.12628. Epub 2017 May 30.

38.

Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism. A Danish nationwide registry-based study.

Sindet-Pedersen C, Langtved Pallisgaard J, Staerk L, Gerds TA, Fosbøl EL, Torp-Pedersen C, Gislason G, Olesen JB.

Thromb Haemost. 2017 Jun 2;117(6):1182-1191. doi: 10.1160/TH16-10-0745. Epub 2017 Mar 16.

PMID:
28300865
39.

Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.

Lamberts M, Staerk L, Olesen JB, Fosbøl EL, Hansen ML, Harboe L, Lefevre C, Evans D, Gislason GH.

J Am Heart Assoc. 2017 Feb 14;6(2). pii: e004517. doi: 10.1161/JAHA.116.004517.

40.

Effect of Reduced Renal Function on Time in Therapeutic Range Among Anticoagulated Atrial Fibrillation Patients.

Bonde AN, Lip GY, Kamper AL, Staerk L, Torp-Pedersen C, Gislason GH, Olesen JB.

J Am Coll Cardiol. 2017 Feb 14;69(6):752-753. doi: 10.1016/j.jacc.2016.11.031. No abstract available.

41.

Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark.

Gadsbøll K, Staerk L, Fosbøl EL, Sindet-Pedersen C, Gundlund A, Lip GYH, Gislason GH, Olesen JB.

Eur Heart J. 2017 Mar 21;38(12):899-906. doi: 10.1093/eurheartj/ehw658.

PMID:
28110293
42.

Thiazolidinediones are associated with a decreased risk of atrial fibrillation compared with other antidiabetic treatment: a nationwide cohort study.

Pallisgaard JL, Lindhardt TB, Staerk L, Olesen JB, Torp-Pedersen C, Hansen ML, Gislason GH.

Eur Heart J Cardiovasc Pharmacother. 2017 Jul 1;3(3):140-146. doi: 10.1093/ehjcvp/pvw036.

PMID:
28028073
43.

Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study.

Gundlund A, Olesen JB, Staerk L, Lee C, Piccini JP, Peterson ED, Køber L, Torp-Pedersen C, Gislason GH, Fosbøl EL.

J Am Heart Assoc. 2016 Nov 19;5(11). pii: e003836.

44.

Atrial fibrillation and risk of stroke: a nationwide cohort study.

Christiansen CB, Gerds TA, Olesen JB, Kristensen SL, Lamberts M, Lip GY, Gislason GH, Køber L, Torp-Pedersen C.

Europace. 2016 Nov;18(11):1689-1697. Epub 2016 Feb 2.

PMID:
26838693
45.

Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study.

Bonde AN, Lip GY, Kamper AL, Fosbøl EL, Staerk L, Carlson N, Torp-Pedersen C, Gislason G, Olesen JB.

Stroke. 2016 Nov;47(11):2707-2713. Epub 2016 Oct 6.

PMID:
27758943
46.

Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study.

Staerk L, Fosbøl EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C, Ozenne B, Gerds TA, Gislason GH, Olesen JB.

Eur Heart J. 2017 Mar 21;38(12):907-915. doi: 10.1093/eurheartj/ehw496.

PMID:
27742807
47.

Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.

Pallisgaard JL, Gislason GH, Torp-Pedersen C, Lee CJ, Sindet-Pedersen C, Staerk L, Olesen JB, Lindhardt TB.

PLoS One. 2016 Aug 25;11(8):e0161768. doi: 10.1371/journal.pone.0161768. eCollection 2016.

48.

Metformin-associated risk of acute dialysis in patients with type 2 diabetes: A nationwide cohort study.

Carlson N, Hommel K, Olesen JB, Gerds TA, Soja AM, Vilsbøll T, Kamper AL, Torp-Pedersen C, Gislason G.

Diabetes Obes Metab. 2016 Dec;18(12):1283-1287. doi: 10.1111/dom.12764. Epub 2016 Sep 21.

PMID:
27534835
49.

Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark.

Staerk L, Fosbøl EL, Gadsbøll K, Sindet-Pedersen C, Pallisgaard JL, Lamberts M, Lip GY, Torp-Pedersen C, Gislason GH, Olesen JB.

Sci Rep. 2016 Aug 11;6:31477. doi: 10.1038/srep31477.

50.

Trends in One-Year Outcomes of Dialysis-Requiring Acute Kidney Injury in Denmark 2005-2012: A Population-Based Nationwide Study.

Carlson N, Hommel K, Olesen JB, Soja AM, Vilsbøll T, Kamper AL, Torp-Pedersen C, Gislason G.

PLoS One. 2016 Jul 26;11(7):e0159944. doi: 10.1371/journal.pone.0159944. eCollection 2016.

Supplemental Content

Loading ...
Support Center